ARVINAS, INC. Increase Decrease In Operating Lease Liability
ARVINAS, INC. (ARVN) reported Increase Decrease In Operating Lease Liability of -$900.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-04
- ARVINAS, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$500.00K.
- ARVINAS, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$400.00K.
- ARVINAS, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$400.00K.
- ARVINAS, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$600.00K.
- ARVINAS, INC. increase decrease in operating lease liability for fiscal 2025 was -$2.00M.
- ARVINAS, INC. increase decrease in operating lease liability for fiscal 2024 was -$1.90M.
- ARVINAS, INC. increase decrease in operating lease liability for fiscal 2023 was -$2.00M.
- ARVINAS, INC. increase decrease in operating lease liability for fiscal 2022 was -$1.90M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$900.00K 10-Q · filed 2026-08-04 | -$1.30M derived: sum of 3 quarters · filed 2026-08-04 | -$1.90M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$400.00K 10-Q · filed 2026-05-11 | -$800.00K derived: sum of 2 quarters · filed 2026-05-11 | -$1.40M derived: sum of 3 quarters · filed 2026-05-11 | -$1.90M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$1.00M derived: sum of 2 quarters · filed 2026-02-24 | -$1.50M derived: sum of 3 quarters · filed 2026-08-04 | -$2.00M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$600.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$1.10M derived: sum of 2 quarters · filed 2026-08-04 | -$1.60M 10-Q · filed 2025-11-05 | -$1.90M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$1.00M 10-Q · filed 2026-08-04 | -$1.30M derived: sum of 3 quarters · filed 2026-08-04 | -$1.90M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$500.00K 10-Q · filed 2026-05-11 | -$800.00K derived: sum of 2 quarters · filed 2026-05-11 | -$1.40M derived: sum of 3 quarters · filed 2026-05-11 | -$1.90M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$900.00K derived: sum of 2 quarters · filed 2026-02-24 | -$1.40M derived: sum of 3 quarters · filed 2026-02-24 | -$1.90M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$600.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$1.10M derived: sum of 2 quarters · filed 2025-11-05 | -$1.60M 10-Q · filed 2025-11-05 | -$2.10M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$1.00M 10-Q · filed 2025-08-06 | -$1.50M derived: sum of 3 quarters · filed 2026-02-24 | -$2.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$500.00K 10-Q · filed 2025-05-01 | -$1.00M derived: sum of 2 quarters · filed 2026-02-24 | -$1.50M derived: sum of 3 quarters · filed 2026-02-24 | -$2.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | -$500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$1.00M derived: sum of 2 quarters · filed 2026-02-24 | -$1.50M derived: sum of 3 quarters · filed 2026-02-24 | -$2.00M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | -$1.00M derived: sum of 2 quarters · filed 2024-10-30 | -$1.50M 10-Q · filed 2024-10-30 | -$1.90M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | -$500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | -$1.00M 10-Q · filed 2024-07-30 | -$1.40M derived: sum of 3 quarters · filed 2025-02-11 | -$1.90M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | -$500.00K 10-Q · filed 2024-05-07 | -$900.00K derived: sum of 2 quarters · filed 2025-02-11 | -$1.40M derived: sum of 3 quarters · filed 2025-02-11 | -$1.80M derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-31 | -$400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | -$900.00K derived: sum of 2 quarters · filed 2025-02-11 | -$1.30M derived: sum of 3 quarters · filed 2025-02-11 | -$1.90M 10-K · filed 2025-02-11 |
| 2022-09-30 | -$500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$900.00K derived: sum of 2 quarters · filed 2023-11-07 | -$1.50M 10-Q · filed 2023-11-07 | -$1.90M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$1.00M 10-Q · filed 2023-08-08 | -$1.40M derived: sum of 3 quarters · filed 2024-02-27 | |
| 2022-03-31 | -$600.00K 10-Q · filed 2023-05-05 | -$1.00M derived: sum of 2 quarters · filed 2024-02-27 | ||
| 2021-12-31 | -$400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$1.30M 10-K · filed 2024-02-27 | ||
| 2021-09-30 | -$900.00K 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |